An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents an increasingly recognized disease entity with rising prevalence of 25% in the general population. Given the epidemic increase, regulatory agencies have defined an unmet medical need and implemented initiatives to expedite the development of drugs for NASH treatment.